Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For Immediate Release
Friday, March 26, 2010 Contact:
Anne A. Oplinger, 301-402-1663 Rapid Development of Drug-Resistant 2009 H1N1 Influenza Reported in Two Cases
Reevaluation of Treatment Strategies for Prolonged Infection Urged
Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Doctors who treat prolonged influenza infection should be aware that even a short course of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment strategies for their patients who have impaired immune function.
Both patients described in the new report developed resistance to the key influenza drug oseltamivir (Tamiflu), and one also demonstrated clinical resistance to another antiviral agent, now in experimental testing, intravenous peramivir, note senior authors Matthew J. Memoli, M.D., and Jeffery K. Taubenberger, M.D., Ph.D. This is the first reported case of clinically significant peramivir-resistant 2009 H1N1 illness, say the scientists. The report is scheduled to appear in print on May 1 in Clinical Infectious Diseases and is now online.
The people in the current case report had immune limitations due to blood stem cell transplants that occurred several years previously. Both recovered from their influenza infections.
"While the emergence of drug-resistant influenza virus is not in itself surprising, these cases demonstrate that resistant strains can emerge after only a brief period of drug therapy," says NIAID Director Anthony S. Fauci, M.D. "We have a limited number of drugs available for treating influenza and these findings provide additional urgency to efforts to develop antivirals that attack influenza virus in novel ways."
The 2009 H1N1 influenza virus is susceptible to just one of the two available classes of anti-influenza drugs, the neuraminidase inhibitors. Besides oseltamivir, other neuraminidase inhibitors are zanamivir (Relenza), which is inhaled, and the intravenously administered investigational drug peramivir. As the H1N1 influenza pandemic unfolded, laboratory tests of virus strains isolated from patients showed that some strains contained a genetic mutation (the H275Y mutation) that makes the virus less susceptible to some neuraminidase inhibitors.
The two people in the current case study had pre-existing medical conditions that impaired their immune system function before contracting 2009 H1N1 flu. Strains of 2009 H1N1 influenza containing the H275Y mutation had been reported previously in people with diminished immune function, but in previous cases the mutation arose after more than 24 days of continuous therapy. In the newly described cases, the mutation appeared after 14 days in one individual and after nine days in the second.
"Although the recommended length of treatment with oseltamivir is five days, it is common for physicians to continue giving this first-line drug longer if the patient does not improve," says Dr. Memoli.
Both people in the current report received oseltamivir for extended periods but they continued to shed virus in their nasal secretions throughout treatment. When one patient’s condition worsened despite 24 days of oseltamivir treatment, doctors administered peramivir for 10 days. The drug did not reduce viral shedding and the patient remained ill, demonstrating what the authors described as clinically significant resistance to peramivir. Next, doctors administered the only other available flu drug, zanamivir, for 10 days. The person then fully recovered.
"Additional, larger studies are needed to further refine our findings,” says Dr. Memoli. “But these cases of rapid appearance of drug-resistant 2009 H1N1 influenza in immune-compromised patients are worrisome and should prompt clinicians to reconsider how they use available flu drugs."
The mutation that allows 2009 H1N1 to resist oseltamivir also significantly reduces the virus's susceptibility to peramivir. If a relatively short course of oseltamivir causes a mutant flu strain to emerge in a particular patient, that person may not respond to peramivir. Zanamivir might be a good choice if a patient does not respond within a few days to oseltamivir, Dr. Memoli says. However, because zanamivir must be inhaled, patients who are very ill and whose breathing is mechanically supported cannot be given zanamivir.
"As clinicians, we should carefully consider our treatment options and use all the drugs available to us wisely. This is especially important in a patient with prolonged infection or when an antiviral drug fails to cure the patient after the recommended course of treatment," says Dr. Memoli.
NIAID scientist Rachel J. Hrabal contributed to this study along with Arash Hassantoufighi and Maryna C. Eichelberger, Ph.D., of the FDA.
Visit www.flu.gov for one-stop access to U.S. government information on influenza. Also, visit NIAID's flu Web portal at http://www3.niaid.nih.gov/topics/Flu/.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
--------------------------------------------------------------------------------
Reference:
MJ Memoli et al. Rapid selection of oseltamivir and peramivir resistant pandemic H1N1 during therapy in two immunocompromised hosts. Clinical Infectious Diseases DOI: 10.1086/651605. (online March 26, 2010)
http://www.articleant.com/p/re/68143-rapid-development-of-drug-resistant-2009-h1n1-influenza-reported.html
Verizon Wireless Apps for DROID Help Customers Stay Organized While Away From Home
LAS VEGAS, and BASKING RIDGE, N.J., March 25 /PRNewswire
*********************
ScanLife Barcode Reader – Together with ScanBuy, Verizon Wireless is helping customers use the cameras on their DROID by Motorola smartphones. Customers can scan a barcode to view product price comparisons without sending, typing or searching. This free app turns DROID into a 2D barcode scanner that recognizes all major barcodes.
http://www.prnewswire.com/news-releases/verizon-wireless-apps-for-droid-help-customers-stay-organized-while-away-from-home-89122657.html
Big market if (when?) barcodes go mainstream.
CTIA: AT&T Wants To Connect Everything To The Internet
By Eric Savitz
AT&T (T) wants to connect more or less everything you can think of to the Internet. The company, which has been boasting about its dominant position in the U.S. smart phone market, is one of a number of participants in this week’s CTIA Wireless show in Las Vegas that expects the Internet of things to rapidly blow past the wireless Internet now dominated by mobile phones.
The strategy became clear this afternoon at a meeting this afternoon with media and analysts.
At the event, Ralph de la Vega, chief of AT&T Mobility and Consumer Markets took a victory lap in the smart phone race. Repeating a theme he touched on in a keynote address yesterday, de la Vega this afternoon noted that AT&T has 30 million 3G data subscribers in the U.S., more than any other carriers, with more than twice the number of smart phones in service than any other U.S. carrier, and customers downloading more apps than any other carriers.
Cisco CTO Padmasree Warrior earlier today predicted that there will be 1 trillion connected devices on the Internet by 2013. That view fits right in with AT&T’s view of the world.
*********************************
http://blogs.barrons.com/techtraderdaily/2010/03/24/ctia-att-wants-to-connect-aboslutely-everthing-to-the-internet/?mod=yahoobarrons
http://www.att.com/gen/press-room?pid=4800&cdvn=news&newsarticleid=30675
Plug Power chair, CEO buy 210K shares
The Business Review
Wednesday, March 24, 2010, 12:22pm EDT
(Albany) - by Pam Allen
The chairman and the CEO of Latham, N.Y.-based Plug Power Inc. have purchased a combined 210,146 shares of Plug Power common stocks.
George McNamee, chairman of the board of directors, bought 160,146 shares for $97,689; CEO Andy Marsh bought 50,000 shares for $29,710.
McNamee now owns 461,854 shares of Plug’s (Nasdaq: PLUG) common stock and has an option to purchase an additional 415,000 shares; Marsh now owns 184,651 shares and has an option to buy 400,000 additional shares.
Marsh said his investment reflects his long-term confidence in the fuel-cell company. His goal for the company in 2010 is revenue in the mid-$40 million to low-$50 million range. Plug had revenue of $12.3 million in 2009 and $17.9 million in 2008.
The company this year plans to dramatically increase shipments of two of its hydrogen-powered fuel cells, Marsh said. Those products are GenDrive, used in fork lifts and other industrial warehouse equipment, and GenSys, a continuously operating power system used for telecommunications operations in remote locations.
“I believe we are well positioned for growth and are on a path to achieving profitability in 2012,” Marsh said.
McNamee has invested in Plug Power since the company was founded in 1997.
“It’s exciting to see this technology and these products finally becoming commercially viable,” McNamee said.
The company has spent more than $500 million to develop its fuel-cell technology and has run in the red since its inception.
Plug reported a net loss of $12.1 million, or 9 cents a share, for the fourth quarter of 2009. That was considerably less than the net loss of $64.3 million, or 69 cents a share, in the year-ago quarter, when the fuel-cell developer recorded a goodwill impairment charge of $45.8 million.
For all of 2009, Plug Power had a net loss of $40.7 million, or 32 cents a share, on revenue of $12.3 million. That compared to the 2008 net loss of $121.7 million, or $1.36 a share, including the fourth quarter impairment charge, on revenue of $17.9 million.
The last time the company’s stocks traded above $1 was in October 2009. Plug can lose its listing on the Nasdaq if the company’s common stock price does not close at or above $1 a share—the minimum closing price required by Nasdaq—for at least 10 consecutive trading days. In December, Nasdaq notified the fuel-cell developer that its stock had not topped $1 per share for at least 30 straight business days. Plug Power has until June 7 to regain compliance with Nasdaq’s minimum closing stock prices.
Stock was trading Wednesday at about 70 cents, up 5 cents from Tuesday’s closing price.
http://www.bizjournals.com/albany/stories/2010/03/22/daily19.html
http://www.secform4.com/insider-trading/1093691.htm
Look here - part of the NeuStar Pilot
Clic2C is created by Mobile Data Systems, Inc., a privately held company based in New York. The company is committed to creating the interactive link between traditional media and its target audience. Using both 1D and 2D barcodes as well as digital watermark encoding technologies, Mobile Data Systems is enabling consumers to interact with product packaging, printed advertisements, using their cameraphone. Brands and Media companies are better able to reach, attract and increase the responsiveness to their products and advertising initiatives using interactive campaigns. Today’s mobile advertising is not about just receiving a message. It’s about interactivity, about selectivity. Mobile Data Systems is considered one of the top thought leaders around digital loyalty and visual search.MDS offers a complete web based carrier grade scalable end to end solution for their clients, in addition to their reader client on just about every smartphone platform in the market today.
http://www.gomocode.com/about-barcodes/barcodes-are-everywhere/hypertouch/mobile-data-systems2
http://www.gomocode.com/about-pilot
That's a bit of an overstatement but it is good to see a CEO with a vested interest in the success of his organization.
http://www.sec.gov/Archives/edgar/data/1476170/000120919110008737/0001209191-10-008737-index.htm
GENCO Purchases 25 Hydrogen Fuel Cell Units from Plug Power Inc.®
Will convert from battery to hydrogen fuel powered lift trucks at Kimberly-Clark Distribution Center
Pittsburgh, PA (Vocus/PRWEB ) March 23, 2010 -- GENCO Supply Chain Solutions, North America’s second largest and a Global Top 50 third-party logistics provider, today announced the purchase of 25 GenDrive™ hydrogen fuel cell power units from Plug Power Inc. for use in lift trucks. The GenDrive units will power the lift trucks at a 450,000 square foot distribution center in Graniteville, SC that GENCO operates for Kimberly-Clark Corporation. The GenDrive units are expected to be received in May and June 2010.
Funding was provided as part of a $6.1 million award made to GENCO in April, 2009 by the U.S. Department of Energy through the American Recovery and Reinvestment Act to accelerate the commercialization of hydrogen fuel cell units and create jobs in fuel cell manufacturing, installation, maintenance and support services. Through this award, GENCO will deploy over 350 GenDrive units at Kimberly-Clark and other companies.
We are excited about the opportunity to move this initiative forward
We’ve had a two-unit pilot program in place with Kimberly-Clark at their Graniteville, SC facility and look forward to the many benefits of the full deployment.
Kimberly-Clark continues to explore new ways to increase safety in the workplace and to minimize the impact of our operations on the environment
GENCO understands the value provided by Plug Power’s GenDrive units
GENCO’s utilization of the GenDrive solution puts it at an advantage over its competition, with respect to both productivity and corporate social responsibility. GENCO is creating a safer environment for its teammates and the community.
"We are excited about the opportunity to move this initiative forward," said Bob Simon, GENCO’s project manager. "We’ve had a two-unit pilot program in place with Kimberly-Clark at their Graniteville, SC facility and look forward to the many benefits of the full deployment."
This sustainable solution eliminates the demand and cost of electricity and significantly reduces greenhouse gas emissions. At the same time, toxic lead-acid is removed from the workplace and replaced with hydrogen, which generates water as a byproduct.
“Kimberly-Clark continues to explore new ways to increase safety in the workplace and to minimize the impact of our operations on the environment,” said Joe DeYoung, Kimberly-Clark distribution operations manager for North American Consumer Products. “We were recently recognized by the U.S. Environmental Protection Agency as a 2010 Energy Star Partner of the Year, and have led the personal product category of the Dow Jones Sustainability World Index (DJSI) for the fifth year in a row. Our pilot at the Graniteville site has been very successful, and we’re pleased to be able to partner with GENCO and Plug Power in expanding hydrogen fuel cell technology to the entire lift truck fleet at this facility.”
“GENCO understands the value provided by Plug Power’s GenDrive units,” said Erik Hansen, vice president and general manager of Plug Power’s Motive Power Division. “GENCO’s utilization of the GenDrive solution puts it at an advantage over its competition, with respect to both productivity and corporate social responsibility. GENCO is creating a safer environment for its teammates and the community.”
GENCO Supply Chain Solutions is North America's second largest and a Global Top 50 third-party logistics provider and the recognized leader in Reverse Logistics. The company manages over 130 operations and 37 million square feet of warehouse space throughout North America for a diverse range of retail, manufacturing and government customers. The company provides initial and ongoing value through a complete range of solutions, including contract logistics, transportation logistics, parcel negotiation and audits, reverse logistics, damage research, product liquidation, pharmaceutical services, government solutions and technology solutions. For more information, visit www.genco.com.
Plug Power Inc. (NASDAQ: PLUG), an established leader in the development and deployment of clean, reliable energy solutions, integrates fuel cell technology into motive and continuous power products. The Company is actively engaged with private and public customers in targeted markets throughout the world. For more information about how to join Plug Power’s energy revolution as an investor, customer, supplier or strategic partner, please visit www.plugpower.com.
Kimberly-Clark Corporation (NYSE: KMB) and its well known global brands are an indispensable part of life for people in more than 150 countries. Every day, 1.3 billion people - nearly a quarter of the world's population - trust K-C brands and the solutions they provide to enhance their health, hygiene and well-being. With brands such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend, Kimberly-Clark holds the No.1 or No. 2 share position in more than 80 countries. To keep up with the latest K-C news and to learn more about the company's 138-year history of innovation, visit www.kimberly-clark.com.
Contact:
Don Rendulic
Director, Marketing and Corporate Communications
412-820-3922
http://www.prweb.com/releases/2010/03/prweb3761434.htm
Nice coverage on CBS news this week.
The Solution
The solution can't come fast enough for patients desperate for help now.
Later this year, Dr. Hans Keirstead of UC Irvine, working with Geron corporation, will begin the first FDA-approved trial of human embryonic stem cells to treat paralyzed patients - within two weeks of injury.
In spinal cord injury, the insulation coating the wires in the cord is destroyed. Electrical messages from the brain can't get past the point of injury - and function is lost.
"It's like you have a bunch of wires that are short-circuiting," Keirstead said. "The tissue that's left doesn't work - because they can't conduct electricity up and down your cord."
Keirstead and his team figured out a way to turn stem cells into a cell that makes insulation for the spinal cord.
Millions of these cells will be injected into the damaged area. The hope is by restoring the insulation, the spinal cord will work again.
"I expect incremental benefits to the humans that get this," Keirstead said. "I think they are going to get better, and I'm just dying to find out if I'm right."
http://www.cbsnews.com/video/watch/?id=6305502n&tag=related;photovideo
http://www.cbsnews.com/stories/2010/03/16/eveningnews/main6305092.shtml
Picked up a few shares here for the first time today, been following it for quite awhile now. GLTA
Ringside VIP seating going fast. I bought a couple of $20 tix just to support my investment, can't attend the event though.
http://smithstix.com/events/item/root/wcfc-presents-the-main-event
Good morning folks, took a position here on yesterdays dip. Glad to be on board, it's also good to see a CEO that is willing to purchase his own stock.
http://www.secform4.com/insider-trading/1212502.htm
NEUSTAR PULLS SIZABLE CROWDS, UNVEILS LATEST ADVANCES AT MOBILE WORLD CONGRESS 2010
With two prominent locations at Mobile World Congress 2010, Neustar was in prime position to showcase the numerous ways the company is “mobilizing the Internet” – and for four extremely busy and productive days, delivered on that potential.
High-profile customers from around the world flocked to Neustar’s Innovation Showcase, which was situated in a high-traffic area near the entrance to a main exhibit hall through which nearly 50,000 people passed each day. Meanwhile, Neustar executives held court with their counterparts at other high-profile companies, as well as with industry analysts and journalists from top-tier media outlets, practically non-stop in the company’s nearby chalet throughout the event.
In addition, Neustar hosted more than 120 people – including numerous executives from the GSM Association (GSMA), an organization representing the interests of the worldwide mobile communications industry – at its networking cocktail reception on February 17. Finally, Vice President Diane Strahan was a panelist in two heavily-attended Mobile Barcode discussions that involved corporate heavyweights such as Coca-Cola, Visa, National Geographic and WPP Group.
“To say that Mobile World Congress 2010 was a huge success for Neustar is a true understatement,” said Jean Foster, Vice President. “This was simply an outstanding team effort, and sets the bar quite high with regard to how we should approach these types of major industry events in the future.”
http://www.neustar.biz/about-neustar/media-and-public-relations/events-and-tradeshows/gsma-mobile-world-congress-2010
WHO: Premature to say H1N1 has peaked
Published: Feb. 24, 2010 at 12:29 PM
GENEVA, Switzerland, Feb. 24 (UPI) -- It is premature to conclude that all parts of the world have experienced peak transmission of H1N1, World Health Organization officials in Switzerland say.
The emergency committee, which makes recommendations to Dr. Margaret Chan, director general of WHO, held its seventh meeting on the determination of the pandemic status.
The committee was provided a detailed analysis of the pandemic worldwide and after asking additional questions and reviewing the evidence and holding extensive discussion, the committee said there was mixed evidence showing declining or low pandemic activity in many countries.
WHO officials say there is new community level transmission activity in West Africa and the committee expressed concern that the winter months of the Southern Hemisphere had not yet started and there was uncertainty whether additional generalized waves of H1N1 activity might occur. Therefore, there is a need not to undermine preparations, the officials say.
The committee advised that it was premature to conclude that all parts of the world have experienced peak transmission of the H1N1 pandemic influenza and that additional time and information was needed to provide expert advice on the status of the pandemic.
http://www.upi.com/Health_News/2010/02/24/WHO-Premature-to-say-H1N1-has-peaked/UPI-83251267032569/
More Signals On H1N1 Wave 3 Start in United States
|
Contributed by ontheway (Reporter)
Thursday, February 25, 2010 7:06
Recombinomics has the story.
Some of the nation's emergency departments are noting increases in flu-like illness cases that appear to be pandemic H1N1, and colleges are reporting the first increase in flu-like illness since the end of November, but it's not clear if these are early signs of a third pandemic flu wave.
The American College of Emergency Physicians (ACEP) said today in a Twitter post that some of its members were anecdotally reporting a new wave of pandemic H1N1 patients coming to emergency departments and asked if other physicians were seeing similar patterns.
Carl Schultz, MD, professor of emergency medicine at the University of California at Irvine, told CIDRAP News that the increase in the number of influenza-like illnesses appears to be real, but he cautioned that many of the cases have not been confirmed as the pandemic H1N1 strain, because many departments stopped specifically testing for it because of low flu activity. Schultz chairs ACEP's disaster preparedness and response committee.
The above comments provide additional data that a third wave in the United States has begun. Reports on flu at universities has increased 52% over last week, which is supported by anecdotal reports from emergency room physicians. The largest number of new student cases was again in North Carolina.
These developments parallel the start of the fall wave. The initial cases were in region 4 and this area has had the highest percent of samples being H1N1 positive. Similarly, state reports showed recent increases in North Carolina and Alabama, while earlier reports describe more severe cases in hospitals in Tennessee and North Carolina.
The initial reports from region 4 may signal the emergence of a more evolved H1N1 since the time between the current outbreak and cases reported in the fall would be greatest. A recent report on Allegheny County, location of metropolitan Pittsburgh found H1N1 antibody in 45% of patients age 10-17. If this population is again being targeted, it is likely that there are re-infections and the new virus has escaped the immune response generated against the fall wave.
Recently released sequences from low reactors indicated that a single nucleotide change could move a sequence into the low reactor category, and recombination was creating new sequences with multiple low reactor polymorphisms, which if additive would lead to widespread vaccine failure and frequent infections of patients infected last year.
Sequence data on new cases, including severe and fatal cases would be useful, as would H1N1 history of these new patients.
http://beforeitsnews.com/story/20243/More_Signals_On_H1N1_Wave_3_Start_in_United_States.html
5. IP Licensing Fee
Participants doing business in the United States and Mexico who do not have an Intellectual Property Licensing Agreement with NeoMedia Technologies, Inc. (“NeoMedia) , a Delaware corporation with a principal place of business at Two Concourse Parkway, Suite 500, Atlanta, Georgia, 30328, must agree to license the NeoMedia patents from Neustar for transactions being presented to the Global Clearinghouse in the United States under the terms and conditions of the separate license agreement attached as Exhibit 4.
b. Promotional Materials and Results
Participant agees to, within thirty (30) days of the completion of a campaign using the Services or by August 15, 2010 (whichever is earlier), to produce, utilizing forms provided by Neustar, customer use case results and information, including the information listed in Exhibit 3 to promote the use of Barcodes. In addition, Participant shall work with Neustar to develop other such reports, documentation, use cases, testimonials and promotional materials that the parties find reasonable to promote the Pilot.
http://www.sec.gov/Archives/edgar/data/1022701/000114420410007797/v174565_ex10-1.htm
Scan this code, which first takes you here -
mc*nsr*54321
you will then be redirected to here
http://getunity.com/visa
http://www.gomocode.com/about-barcodes/visa-check-your-balance-contest
Notice the 'Powered by" banners at the bottom.
This one feels a little different than previous pilots though.
http://www.gomocode.com/about-pilot
Try this website. I have never been able to get Neoreader for my BB Tour until now either. It shows the reader available for the Nokia N97.
http://www.getreader.com/getreader/select_make
Shionogi seeks OK for influenza drug for children
Mon Feb 15, 2010 2:02am ESTStocks
TOKYO, Feb 15 (Reuters) - Japanese drugmaker Shionogi & Co said on Monday it has applied for regulatory approval to make and sell its intravenous influenza drug Rapiacta to treat children in Japan.
The drug, whose generic name is peramivir, has been available in Japan for use in adults since Jan. 27. Biocryst (BCRX.O), the original developer of the drug, has been selling it in the United States for severely ill patients since October.
Shionogi, based in Osaka, bought the rights to develop and sell it in Japan and Taiwan from BioCryst in 2007 for $35 million and has said it expects the drug to bring in annual sales of at least 5 billion yen.
Shares of both drugmakers soared in the wake of the H1N1 flu outbreak, and BioCryst said recently that a milder-than-expected pandemic could slow order rates.
Separately, Fujifilm Holdings said its pharmaceuticals unit Toyama Chemical has started Phase II clinical testing of the experimental influenza drug T-705 in the United States.
Toyama said in October it had begun Phase III studies in Japan on the same drug, whose generic name is favipiravir.
In both countries Phase III is the final stage of clinical testing before firms submit data to regulators for approval. (Reporting by Yumiko Nishitani; Editing by Hugh Lawson)
http://www.reuters.com/article/idUSTOE61E02I20100215?type=marketsNews
Iain McCready
Featured Innovator Featured Article
February 12, 2010
By Maxfield Fulton, Analyst, Auster Capital Partners
With the proliferation of the latest 3G (and soon 4G) mobile devices, a new breed of applications, and networks capable of handling the increased volume of data traffic, a new era in advanced mobile communications is about to begin. NeoMedia CEO Iain McCready spends a few minutes answering a few questions on why the mobile barcode industry is ready for prime time.
Story continues below ?
What kind of phone do you use?
Various, but generally a Nokia (News - Alert) N85 and an iPhone.
What sort of applications have you downloaded since you got your phone?
Many, but lately I have used barcode reading, price comparison, and product location software most frequently.
Which applications do you use most often?
Barcode reading and maps.
How do you usually find out about new mobile applications?
Through application retailers or friends.
What was the last ad you can remember seeing for a mobile application?
Good question! Probably related to the iPhone (News - Alert), so it advertised multiple applications.
What sticks out in your mind as a particularly creative or unique application?
Barcode reading, of course!
What would you like to see mobile barcoding used for in the future?
On the pull side,a advertising, mobile search, product information (extended packaging) and social networking on the pull side. On the push side, paperless ticketing and couponing.
Barcode transactions are experiencing growth that puts them on a schedule to surpass SMS - when do you see this happening?
I think to surpass SMS any time soon is a bit ambitious! We should see good transaction volumes in Q4 of this year.
What do you like most about the mobile barcodes industry?
The fact that we’re now ready. We’ve agreed on open standards barcodes, the elements of the system, clearing and using the indirect method. It should be a big year ahead.
What role does mobile innovation play in your job?
Innovation is happening everywhere. We are constantly looking for the next step and next big thing.
Do you think phones should come with barcode-reading software pre-installed?
Well, soon Sony Ericsson (News - Alert) phones will feature barcode-reading software on all of their phones. I’m sure others will follow.
http://mobile-barcode.tmcnet.com/topics/featured-innovator/articles/75443-ia-mccready.htm
Unilife Corporation to Commence Trading on the NASDAQ Global Market
SEC DECLARES FORM 10 EFFECTIVE
Lewisberry, P.A. (February 12, 2010) Unilife Corporation (Company) (ASX: UNS, NASDAQ: UNIS) today announced that the US Securities and Exchange Commission (SEC) declared the Company's Form 10 registration statement effective, clearing the path for Unilife Corporation's listing on the NASDAQ.
The Company expects trading of Unilife Corporation common stock to commence on NASDAQ on or around February 16, 2010 under the ticker "UNIS".
Alan Shortall, CEO of Unilife, stated, “I would like to thank the Unilife team for the completion of this significant corporate milestone. In particular, I wish to note the important contribution made by the Unilife Finance department, and our Australian and US legal representatives DLA Phillips Fox and DLA Piper who worked tirelessly to achieve this approval within our projected timeframe.
“Despite severe weather conditions in the eastern portion of the US that caused a shutdown of all Federal Government offices in Washington, D,C, and restricted operations in both Pennsylvania and New York City, our team has been able to work co-operatively to complete the work necessary to achieve this result. I must compliment the Unilife team and our advisors for an outstanding effort.”
The Company also wishes to advise that by the time trading of Unilife common stock commences on NASDAQ, it will have published on its website (www.unilife.com) a list of Frequently Asked Questions (FAQs) to support shareholders wishing to trade on either the ASX or NASDAQ. The Company has also now opened an Investor Hotline to assist with shareholder enquiries during this period. The enquiry line numbers are 1800 632 680 (Australia toll free), +1 866 496 5819 (US toll free) and or +61 2 8256 3394 (International).
About Unilife Corporation
Unilife Corporation are a U.S based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
Unilife’s main product is the Unifill™ ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. The Company has a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill™ syringe and is funding an industrialization program for the product. In addition, Unilife has retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission.
Investor Contacts (US):
Todd Fromer / Garth Russell
KCSA Strategic Communications
+ 1 212-682-6300
http://www.unilife.com/index.php?option=com_content&task=view&id=596&Itemid=76
That is what I was thinking, wish I had bought more. The more DD I do the better I like the prospects.
Shionogi markets new flu drug
OSAKA (Kyodo) Shionogi & Co. has released a new drug to treat swine flu.
The drug, which went on the market Wednesday, is named Rapiacta — the generic name is peramivir — and is administered via an intravenous drip.
It is the third drug to treat the new H1N1 flu strain to be made available in Japan, following Tamiflu and Relenza.
Unlike these two drugs, which are administered orally, the new drug can be used to treat patients who can't take medicines orally, such as people on a respirator, the firm said.
The company plans to supply enough doses for 700,000 patients by the end of March.
http://search.japantimes.co.jp/cgi-bin/nn20100128b2.html
Nice little bounce today.
1. Name and Address of Reporting Person *
SANDERS CHARLES A
BIOCRYST PHARMACEUTICALS INC [ BCRX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable) __ X __ Director
Common Stock 02/08/2010 Purchase 5,000 A $ 6.66
http://www.secform4.com/insider-trading/1022936.htm
http://www.secform4.com/filings/882796/000112760210003943.htm
Hello folks, I took a starter position here today. Slide presentation from BCRX website provides good insight into the companies potential IMO.
http://files.shareholder.com/downloads/BCRX/838721938x0x349249/08932843-e42e-4b51-8293-e9926933a1f9/BCRX%20BIO%20CEO%20conf%20slides%2008Feb10%20inroom.pdf
Here is a link to the latest filing.
http://www.sec.gov/Archives/edgar/data/1476170/000095012310007104/0000950123-10-007104-index.htm
Pardon my ignorance but what does HC stand for? TIA
REGISTRY & CLEARINGHOUSE
3.1 Intention. Neustar intends to develop, deploy and administer a Registry and Clearinghouse, whereby on behalf of Resolution Authorities, Code identifiers and related conditions of use are registered, associated, and communicated.
Currently, Neustar envisions that a Registry may perform the following activities or enable the following functions:
· perform a documentary and referential function for Codes and their issuing entities
· apply terms and conditions of the Governing Authority to business policies for registering both Codes and authorities for the use of Codes
· serve as the definitive authority for clearing services for Code relationships
Currently, Neustar envisions that a Clearinghouse may perform the following activities or enable the following functions:
· receive Code strings from devices
· reference the appropriate Registry to determine Resolution Authority
· forward the Code strings to the applicable Resolution Authority
· receive from the Resolution Authority a content-related response in the form of a uniform resource identifier, or similar identifier, or content as specified by the Resolution Authority
· forward that identifier to the requesting device
http://www.sec.gov/Archives/edgar/data/1022701/000114420410004251/v172625_ex10-1.htm
That sure sounds a lot like this.
http://www.wipo.int/pctdb/en/wo.jsp?WO=WO/2009/114710
Item 1.01. Entry Into a Material Definitive Agreement
On January 22, 2010, NeoMedia Technologies, Inc., a Delaware corporation (the “Company”), entered into an Amended and Restated License Agreement (the “Agreement”) with NeuStar, Inc. (“NeuStar”). The Agreement amends and restates an agreement entered into between the parties on October 2, 2009. The Agreement extends the territory covered by the Agreement to include the United Mexican States and extends the licensed patents covered by the Agreement to include the Company’s machine-readable code resolution technology patents granted in the United Mexican States.
The Agreement has a term of four (4) years, subject to certain renewal and termination provisions set forth in the Agreement. Pursuant to the Agreement, the Company agreed to grant to NeuStar the right to sublicense certain of the Company’s intellectual property rights with respect to machine-readable code resolution technology. Also, the Company agreed to grant to NeuStar a royalty-free license with respect to certain patents related to such technology. The Agreement also contains certain non-competition, indemnification and confidentiality terms.
The summary of the Agreement provided herein is qualified in its entirety by the terms of the Agreement, which is fully set forth and attached hereto as Exhibit 10.1, which is incorporated by reference herein.
ITEM 8.01. OTHER EVENTS.
On January 28, 2010, the Company issued a press release announcing the Agreement (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and it is incorporate herein in its entirety by reference thereto.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibit 10.1 Amended and Restated License Agreement, dated January 22, 2010, by and between the Company and NeuStar, Inc. Provided herewith
Exhibit 99.1 Press release, dated January 28, 2010. prrovided herewith
http://www.sec.gov/Archives/edgar/data/1022701/000114420410004251/v172625_8k.htm
http://www.sec.gov/Archives/edgar/data/1022701/000114420410004251/v172625_ex10-1.htm
Im about done here for the day but I will leave you with one question to ponder - If you were holding shares that you knew were worth $4.00 (because you might be privy to information that others are not) would you let them go for $.60?
Regards,
So I guess all the questions about why YA demanded a RS have been answered now.
Closing low on Jan 14th ($.0058)- right after the 8K. Current conversion basis with 30 day look back period and the lowest close since sept 14, 2009 (.004 four months ago.)
Wouldn't matter as long as the look back conversion had not fallen below $.58 and no additional debt was incurred.
Our future resides in those numbers (conversion price in effect and market value of the company) if there is a sale.
Make your own judgements as to the value of the Co. and the amount of debt due.
IMO IMO IMHO
I'll answer my own question using your numbers (not mine)
OS post split = 24million
Conversion price in effect = $.58
$.58 @ 93% (weighted average conversion formula) =$.54
YA debt due = $40 million
$40 mil divide by $.54 = 74,074,074
24 mil + 74 mil = 98 mil fully diluted share count.
$400,000,000 divided by 98,000,000 = $4.08 per fully diluted share.
Ya gets 75% commoners get 25% (74m/98m)
YA = $300m
Shareholders = $100M
If you could by at $.60 and sell at $4.08 wouldn't you?
Not a recommendation at all here folks, just demonstrating that little changes in numbers make big differences.
Arpvrp, what do your numbers look like if you use the actual current lookback of $.0058, (125 days not in effect yet and sept low close of .004 should be outdated by the time of the shm) the actual weighted average conversion factor of 93% and a sale price of $400mil?
Buy shares and hold the line at $.0058 or get out! IMO
I doubt that YA ever exceeded 4.99%. More than 200 million shares were traded on the day in question ( right after USPTO decision 2/19 ?), if my memory serves me correctly. Im sure they dumped half in the morning and reloaded for the afternoon. If you sell 4.99% then aquire 4.99% even in the same day, you did not exceed 4.99%!